1. Introduction {#sec1}
===============

The s-triazine and its derivatives have a wide range of pharmaceutical benefits: antiviral, antimalarial, antibacterial, anti-inflammatory, antileukemia, anticancer, and anti-HIV activities \[[@B1]--[@B4]\]. Many triazine analogues are utilized as a building block for the construction of multisite ligand systems \[[@B5], [@B6]\]. A number of triazine analogues were tested for ion extraction of metal ions which have been reviewed \[[@B7], [@B8]\]. Some triazine derivatives with pyrazole, functioning at the least conventional habiliments, are screened and identified as potential inhibitors of photosynthetic electron transport \[[@B9]\]. In literature survey, it was refereed that the organic s-triazine\'s derivative compounds and transition metal complexes have been found to be effective in the field of nonlinear optical activity (NLO) \[[@B10]--[@B12]\] that can act as an auxiliary acceptor in NLO chromophores. Further advantages in considering the s-triazine as central moiety are its symmetric nature by which it will be possible to chemically tune its NLO nature by mono- or disubstitution \[[@B13], [@B14]\]. 1,3,5-Triazine is considered to be a remarkable in supramolecular chemistry since it can take part in all types of interactions, namely, coordination, hydrogen bonds, electrostatic and charge-transfer attractions, and aromatic-stacking interactions \[[@B15]\]. Triazine derivatives have been widely used in several fields such as herbicide \[[@B16], [@B17]\]. In materials chemistry 1,3,5-triazine derivatives have been used as acceptors in star-shaped systems \[[@B18]\], liquid crystals \[[@B19]\], redox active chromophores \[[@B20]\], photovoltaic devices \[[@B21]\], and blue phosphorescent \[[@B22]\]. Also, it was used as functional materials \[[@B23]\], catalysts \[[@B24]\], absorption of surfactants \[[@B25]\], nanoporous membranes for desalination \[[@B26]\], and cathodes for lithium batteries \[[@B27], [@B28]\].

In connection of our previously work \[[@B29]\], this article aimed to synthesized new platinum(IV) and palladium(II) complexes with four triazine ligands ([Figure 1](#fig1){ref-type="fig"}) and checked the biological property and anticancer significance.

2. Materials and Methods {#sec2}
========================

2.1. Chemicals {#sec2.1}
--------------

The PtCl~4~ and PdCl~2~ salts were received from Sigma-Aldrich Chemical Corporation, St. Louis, Mo, USA.

2.2. Synthesis of Trisubstituted s-Triazine Derivative Ligands {#sec2.2}
--------------------------------------------------------------

Synthesis of*N*^*2*^*,N*^*4*^*,N*^*6*^-triaryl-1,3,5-triazine-2,4,6-triamine primary nucleus ([Figure 2](#fig2){ref-type="fig"}) was carried out as described in literature \[[@B30], [@B31]\]. The synthesis of**L**^**1**^,**L**^**2**^,**L**^**3**^, and**L**^**4**^ triazine ligands was carried out according to our previously work \[[@B29]\],**L**^**1**^ prepared by stirring the mixtures of 2-aminopyrimidine with 6-chloro-N^2^-(4-chlorophenyl)-N^4^-di(pyrimidin-2-yl)-1,3,5-triazine-2,4-diamine in dioxane at refluxed temperature;**L**^**2**^ prepared by stirring the mixtures of 2-aminothiazole with 6-chloro-N^2^-(4-chlorophenyl)-N^4^-(pyrimidin-2-yl)-1,3,5-triazine-2,4-diamine in dioxane at refluxed temperature;**L**^**3**^ prepared by stirring the mixtures of 2-aminopyrimidine with 4,6-dichloro-N^2^-(1H-1,2,4-triazol-3-yl)-1,3,5-triazin-2-amine in dioxane 50°C;**L**^**4**^ prepared by stirring the mixtures of 2-aminopyrimidine with 4,6-dichloro-N-( 4-chlorophenyl)-1,3,5-triazin-2-amine in dioxane 50°C.

2.3. Synthesis of Pt(IV) and Pd(II) Complexes {#sec2.3}
---------------------------------------------

A hot methanolic solution of the metal chloride (Pt(IV) and Pd(II)) (1 mM) was added to the hot methanolic solution of ligands (**L**^**1**^,**L**^**2**^,**L**^**3**^, or**L**^**4**^) (1 mM). The mixed solutions were stirred and refluxed at 70°C for 6 hrs. The colored precipitates thus separated out were washed with methanol and dried in*vacuo*.

2.4. Instrumentals {#sec2.4}
------------------

No.Type of analysisModel of the instruments(i)Elemental analysesPerkin Elmer CHN 2400 (USA)(ii)Metal ionsgravimetrically(iii)Melting pointMPS10--120(iv)Molar conductivitiesJenway 4010 conductivity meter(v)Infrared spectraBruker Alpha FTIR Spectrophotometer(vi)UV-Vis absorption spectraUV2 Unicam UV/Vis Spectrophotometer(vii)Magnetic momentsMagnetic Susceptibility Balance, Sherwood Scientific, Cambridge Science Park, Cambridge, England(viii)^1^H,^13^C-NMR spectraOxford YH-300 NMR spectrometer(ix)Mass spectra70 eV using AEI MS 30 mass spectrometer(x)Thermal studies TG/DTGMettler Toledo AG thermogravimetric analyzer(xi)SEMQuanta FEG 250 equipment(xii)XRDX \'Pert PRO PANanalytical X-ray powder diffraction(xiii)TEMJEOL 100s microscopy

2.5. Antimicrobial Study {#sec2.5}
------------------------

Antimicrobial evaluations of the investigated samples were assessed by a modified Kirby-Bauer disc diffusion method \[[@B32], [@B33]\].

2.6. Anticancer Study {#sec2.6}
---------------------

All tested samples were checked against human colon and lung cancer cell line by using neutral red (NR) technique \[[@B34]\].

3. Results and Discussion {#sec3}
=========================

3.1. Microanalytical and Physical Data {#sec3.1}
--------------------------------------

All the platinum(IV) and palladium(II) s-triazine derivative complexes were obtained as colored solids by the reaction of ligands (**L**^**1**^,**L**^**2**^,**L**^**3**^, and**L**^**4**^) with anhydrous metal chloride salts (PtCl~4~ and PdCl~2~). The experimental of elemental analyses of the ligands and their metal complexes ([Table 1](#tab1){ref-type="table"}) are in good agreement with the calculated data. The ligands and their metal (IV/II) complexes are stable at room temperature and soluble in common organic solvents such as (DMSO and DMF). According to the elemental analysis and spectroscopic assignments, the chelating sites and geometry have been suggested and are displayed in [Figure 3](#fig3){ref-type="fig"}. The molar conductance of both free s-triazine derivative ligands and their Pt(IV) and Pd(II) complexes in 10^−3^ M of DMSO solution is in the range of 64.7--139.3 *μ*S, which reveals the electrolytic behavior of the complexes \[[@B35]\]. Melting points of all complexes have values more than \>300°C due to thermal stability properties.

3.2. FT-IR Spectra {#sec3.2}
------------------

Peaks at 1620, 1560, 1485, 740, and 627 cm^−1^ present in**L**^**1**^,**L**^**2**^,**L**^**3**^, and**L**^**4**^ s-triazine derivatives ligands can be assigned for the C=N~pyrimidine~, C=C, C=N, C--S, and C--Cl stretching vibrations. The FT-IR spectra of the ligands show a strong-to-medium strong bands at 1488 cm^−1^ (**L**^**1**^), 1485 cm^−1^ (**L**^**2**^), 1510 cm^−1^ (**L**^**3**^), and 1484 cm^−1^ (**L**^**4**^) which are assigned to *ν*(C=N) group of triazine \[[@B36]\]. Infrared spectral data of the**1**--**8** complexes ([Table 2](#tab2){ref-type="table"}; [Figure 4](#fig4){ref-type="fig"}) usually a lot of valuable information is provided about the coordination mechanism. The free ligands which exhibit a band at 1623 cm^−1^ (**L**^**1**^), 1619 cm^−1^ (**L**^**2**^), 1621 cm^−1^ (**L**^**3**^), and 1619 cm^−1^ (**L**^**4**^) are assigned to *ν*(C=N) of pyrimidine and triazole rings. In case of complexes, this band is shifted to 1698--1667 cm^−1^ region attributed to nitrogen atom of (C=N) coordination to metal ion. The ligands shows a medium strong band at 1510--1484 cm^−1^, which is characteristic of the *ν*(C=N) group in s-triazine \[[@B37], [@B38]\]. This band shifted to lower frequency of 1396--1382 cm^−1^ upon complexation which indicates that triazine ring nitrogen is one of the coordinating atoms in the ligand \[[@B38]\]. The *ν*(N--H) stretching frequency of pyrimidine/triazole rings exhibited at 3260--3112 cm^−1^ was shifted to lower wavenumbers after complexation due to the reduction of lone pair repulsive forces on the nitrogen atoms \[[@B39]\]. In the FT-IR spectra of complexes, the medium-weak bands appeared at 570--440 cm^−1^ regions which can be assigned to *ν*(M--N) \[[@B40]\] and confirm the interaction between metal and ligand.

3.3. Electronic and Magnetic Studies {#sec3.3}
------------------------------------

The electronic spectra of \[Pt~3~(**L**^**1**^)~2~(Cl)~9~(H~2~O)~3~\].3Cl.3H~2~O (**1**), \[Pt~3~(**L**^**2**^)~2~(Cl)~9~(H~2~O)~3~\].3Cl (**2**), \[Pt~3~(**L**^**3**^)~2~(Cl)~9~(H~2~O)~3~\].3Cl (**3**), and \[Pt~2~(**L**^**4**^)~2~(Cl)~6~(H~2~O)~2~\] .2Cl.4H~2~O (**4**) complexes which displayed charge-transfer transitions may interfere and prevent the observation of all the expected bands \[[@B41], [@B42]\].The distinct bands at 300--311 and 337--396 cm^−1^ are attributed to a combination of metal ligand charge transfer (M→L~CT~) and d--d transition band. The other weak band at 429--437 cm^−1^ is attributed to combination of N→Pt(IV) metal charge transfer (L*π*→M~CT~) and d--d transition bands. The Pt(IV) complexes are found to be diamagnetic character, so the Pt(IV) complexes must be octahedral geometry. The Pt(IV) is d^6^ system and four bands are expected due to ^1^A~1g~→  ^3^T~1g~, ^1^A~1g~→  ^3^T~2g~, ^1^A~1g~→  ^1^T~1g~, and ^1^A~1g~→  ^1^T~2g~ transitions. The shift to lower frequency after complexation is due to the binding between Pt(IV) ion nitrogen atom of triazine, pyrimidine, thiazole, and triazole rings. Palladium(II) complexes have diamagnetic properties. The electronic absorption spectra of palladium(II) complexes have distinguished bands at (300 nm), (312 and 352 nm), (309, 334 and 391 nm), and (296, and 339 nm) for**L**^**1**^,**L**^**2**^,**L**^**3**^, and**L**^**4**^ ligands, respectively, due to Pd-L^n^~CT~ charge-transfer transitions.

3.4. ^1^H, ^13^C-NMR Spectra {#sec3.4}
----------------------------

*Complex* ***1***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.26 (t, H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.30 (t, H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.34 (d, 2H,*J =* 4.5 Hz,*p*-Chloroaniline*C*~*3*~*H*), 7.39 (d, 2H,*J =* 9.9 Hz,*p*-Chloroaniline*C*~*2*~*H*), 8.81 (d, 2H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 8.91 (d, 2H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 9.82 (s, 1H, NH), 11.19 (s, 1H, NH), 12.06 (s, 1H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 111.4, 113.8, 117.9, 123.9, 130.7, 140.1, 144.1, 147.5, 153.1, 157.1, 159.2, 163.4, 163.9, 166.2, and 169.7 (Ar-C, C=C, C=N).

*Complex* ***2***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.34 (d, 2H,*J =* 7.2 Hz, thiazole*C*~*5*~*H*), 7.38 (t, 4H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.44 (d, 4H,*J =* 4.5 Hz,*p*-Chloroaniline*C*~*3*~*H*), 7.77 (d, 4H,*J =* 9.9 Hz,*p*-Chloroaniline*C*~*2*~*H*), 7.86 (d, 2H,*J =* 6.3 Hz, thiazole*C*~*4*~*H*), 8.09 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 9.51 (s, 2H, NH), 11.18 (s, 2H, NH), 12.08 (s, 2H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 112.5, 114.0, 114.9, 123.2, 132.5, 145.2, 151.4, 152.9, 155.4, 157.0, 158.8, 162.0, 163.5, and 172.2 (Ar-C, C=C, C=N, C-S).

*Complex* ***3***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.23 (t, 2H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.32 (s, 2H, triazole*C*~*5*~*H*), 8.45 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 8.91 (s, 2H, NH), 11.22 (s, 2H, NH), 11.46 (s, 1H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 115.8, 142.8, 146.5, 155.0, 156.2, 159.2, 163.8, 163.9, and 167.1 (Ar-C, C=C, C=N, C-Cl).

*Complex* ***4***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.35 (t, 4H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.39 (d, 4H,*J =* 4.5 Hz,*p*-Chloroaniline*C*~*3*~*H*), 7.44 (d, 4H,*J =* 9.9 Hz,*p*-Chloroaniline*C*~*2*~*H*), 7.76 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 9.50 (s, 2H, NH), 11.19 (s, 2H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 111.9, 118.0, 123.1, 132.4, 144.4, 147.9, 153.5, 156.8, 161.8, 166.6, and 172.1 (Ar-C, C=C, C=N, C-Cl).

*Complex* ***5***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.32 (t, 2H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.35 (t, 2H,*J =* 4.5 z, pyrimidine*C*~*5*~*H*), 7.41 (d, 4H,*J =* 4.5 Hz,*p*-Chloroaniline*C*~*3*~*H*), 7.46 (d, 4H,*J =* 9.9 Hz,*p*-Chloroaniline*C*~*2*~*H*), 8.57 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 7.79 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 9.55 (s, 2H, NH), 11.19 (s, 2H, NH), 11.20 (s, 2H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 113.1, 115.1, 120.1, 123.8, 129.4, 141.7, 147.0, 149.8, 152.4, 157.7, 159.6, 163.1, 163.9, 165.8, and 171.1 (Ar-C, C=C, C=N).

*Complex* ***6***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.33 (d, 2H,*J =* 7.2 Hz, thiazole*C*~*5*~*H*), 7.36 (t, 4H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.45 (d, 4H,*J =* 4.5 Hz,*p*-Chloroaniline*C*~*3*~*H*), 7.78 (d, 4H,*J =* 9.9 Hz,*p*-Chloroaniline*C*~*2*~*H*), 7.81 (d, 2H,*J =* 6.3 Hz, thiazole*C*~*4*~*H*), 8.12 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 9.55 (s, 2H, NH), 11.20 (s, 2H, NH), 12.02 (s, 2H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 110.2, 113.1, 115.8, 123.8, 131.8, 146.1, 150.3, 152.1, 155.0, 156.6, 158.1, 161.2, 163.1, and 173.4 (Ar-C, C=C, C=N, C-S).

*Complex* ***7***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.21 (t, 2H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.39 (s, 2H, triazole*C*~*5*~*H*), 8.46 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 8.92 (s, 2H, NH), 11.20 (s, 2H, NH), 11.48 (s, 1H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 116.5, 141.9, 147.4, 154.4, 155.9, 159.8, 163.1, 164.5, and 168.8 (Ar-C, C=C, C=N, C-Cl).

*Complex* ***8***. ^1^H-NMR (DMSO-*d*~6~): *δ* = 7.33 (t, 4H,*J =* 4.5 Hz, pyrimidine*C*~*5*~*H*), 7.36 (d, 4H,*J =* 4.5 Hz,*p*-Chloroaniline*C*~*3*~*H*), 7.46 (d, 4H,*J =* 9.9 Hz,*p*-Chloroaniline*C*~*2*~*H*), 7.81 (d, 4H,*J =* 4.5 Hz, pyrimidine*C*~*4,6*~*H*), 9.55 (s, 2H, NH), 11.20 (s, 2H, NH). ^13^C-NMR (DMSO-*d*~6~): *δ* = 113.5, 119.2, 122.9, 130.5, 145.5, 149.4, 153.1, 157.4, 162.7, 165.6, and 171.8 (Ar-C, C=C, C=N, C-Cl).

The ^1^H-NMR spectral data of the synthesized Pt(IV) and Pd(II) complexes have been shifted to downfield because of formation metal chelating through the nitrogen atoms of triazine, pyrimidine, thiazole, and triazole rings.

3.5. Thermogravimetric Studies {#sec3.5}
------------------------------

Thermal analyses (TG-DTG) were performed under N~2~ atmosphere. The thermogravimetric and differential thermogravimetric curves of the synthesized Pt(IV) (**1**--**4**) and Pd(II) (**5**--**8**) complexes are shown in Figures [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}. [Table 3](#tab3){ref-type="table"} refereed to the thermal decomposition assignments of all complexes from room temperature till 1000°C.

3.6. X-Ray Diffraction Spectra {#sec3.6}
------------------------------

XRD diffraction patterns of the solid Pt(IV) and Pd(III) triazine complexes have been displayed in [Figure 7](#fig7){ref-type="fig"}. The diffraction patterns of new Pt(IV) and Pd(II) complexes at 2*θ* values are (11.094, 13.585, 15.041, 15.840, 19.929, 22.276, 23.198, 30.360, 33.693, 39.780, 47.720°), (5.082, 12.894, 19.845, 29.786°), (12.861, 16.426, 17.438, 19.695, 22.031, 26.390, 35.265°), (13.078, 19.773, 29.893, 35.342, 45.307°), (16.712, 27.173, 28.562, 31756, 37.958, 45.472, 56.157, 57.440, 59.071°), (4.948, 10.051, 13.820, 16.705, 17.357, 19.608, 20.512, 24.738, 26.567, 27.247, 29.786, 37.806, 56.168, 57.332, 59.199°), (5.527, 11.110, 16.704, 18.605, 27.263, 28.547, 29.090, 33.708, 37.678, 51.690, 56.690, 56.193, 57.367, 59.096, 79.472°), and (16.839, 27.384, 28.680, 37.851, 48.826, 50.279, 56.287, 57.573, 59.194°) for the complexes**1**--**8**, respectively. The particle size was estimated using Scherrer\'s equation \[[@B43]\]. The XRD patterns due to metallic platinum are agreement with JCPDS PDF card no. 04-0802 standard card \[[@B44]\] with (111), (200), (220) planes, respectively. Powder XRD patterns of Pd(II) complexes are shown in [Figure 7](#fig7){ref-type="fig"}. These spectra included distinguish patterns at 2*θ* = 37.678, 51.690, 59.096, and 79.472° assigned to (111), (200), (220), and (311) of Pd metal with fcc structure matching with JCPDS file no. 87-0638 \[[@B45]\]. This result confirms the presence of metallic Pd with fcc structure. The grain sizes of platinum(IV) and palladium(II) complexes are existed within 42--50 and nm according to highest distinguish peaks.

3.7. Scanning and Transmission Electron Microscopes {#sec3.7}
---------------------------------------------------

The SEM photos of Pt(IV) and Pd(II) complexes**1**--**8** are shown in [Figure 8](#fig8){ref-type="fig"}. These images reveal that the surface of all complexes is homogeneous with various morphological view because of the role of Pt(IV) and Pd(II) metal ions in the rearrangement of grains.

According to the TEM technique ([Figure 9](#fig9){ref-type="fig"}), the average of particle size of platinum(IV) complexes existed within 15--92 nm.

3.8. Biological Studies {#sec3.8}
-----------------------

### 3.8.1. Antibacterial Assessments {#sec3.8.1}

[Table 4](#tab4){ref-type="table"} refers to the antibacterial activity of the free triazine ligands (**L**^**1**^,**L**^**2**^,**L**^**3**^, and**L**^**4**^) comparable with its platinum(IV) and palladium(II) complexes (**1**--**8**) against*Staphylococcus aureus* (G+),*Escherichia coli* (G−), and fungi (*Aspergillus flavus* and*Candida albicans*). All complexes beside the four free ligands which have not any significant inhibitory against both respected fungi except for complexes of**1**,**3**,**5**,**7,** and**8** have moderate inhibitory against*Aspergillus flavus*. All complexes have a moderate bacterial inhibitory in comparison with ampicillin standard drug. The variation in the activity of different metal complexes against different microorganisms depends on either the impermeability of the cells of the microbes or the differences in ribosomes in microbial cells \[[@B46], [@B47]\].

### 3.8.2. Anticancer Assessments {#sec3.8.2}

[Table 5](#tab5){ref-type="table"} and [Figure 10](#fig10){ref-type="fig"} refer to the IC~50~ results of the free triazine ligands and its Pt(IV) complexes. From these data, it is clearly deduced that the \[Pt~3~(**L**^**3**^)~2~(Cl)~9~(H~2~O)~3~\].3Cl (**3**) complex has an efficiency against human colon and human lung cancer A549 cell lines rather than its corresponding free**L**^**3**^ ligand.
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![TGA-DTG curves of Pd(II) complexes**5**--**8**.](BMRI2019-9835745.006){#fig6}

![](BMRI2019-9835745.007){#fig7}

![SEM photos of Pt(IV) and Pd(II) complexes**1**--**8**.](BMRI2019-9835745.008){#fig8}

![TEM photos of Pt(IV) complexes**1**--**4**.](BMRI2019-9835745.009){#fig9}
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###### 

Microanalytical and physicochemical data of ligands and their complexes.

  Compounds*∗*   Color            Λ(*μ*S)   Elemental analyses found(Calc.)   Yield, %                       
  -------------- ---------------- --------- --------------------------------- ---------- --------- --------- ----
  **1**          Yellow           126.8     (21.44)                           (2.01)     (14.71)   (30.73)   77
  21.32          1.96             14.57     30.66                                                            
                                                                                                             
  **2**          Brown            70.6      (20.66)                           (1.63)     (13.55)   (31.46)   72
  20.54          1.54             13.50     31.32                                                            
                                                                                                             
  **3**          Green            64.7      (13.13)                           (1.22)     (17.02)   (35.55)   71
  13.09          1.18             17.00     35.50                                                            
                                                                                                             
  **4**          Pale yellow      95.6      (22.64)                           (2.19)     (14.22)   (28.29)   69
  22.56          2.13             14.16     28.11                                                            
                                                                                                             
  **5**          Dark brown       139.3     (28.64)                           (2.69)     (19.65)   (22.39)   75
  28.56          2.57             19.54     22.31                                                            
                                                                                                             
  **6**          Red brown        82        (26.77)                           (2.53)     (17.56)   (22.24)   70
  26.71          2.51             17.49     22.19                                                            
                                                                                                             
  **7**          Brownish green   106.7     (17.70)                           (2.15)     (22.94)   (26.14)   74
  17.65          2.09             22.90     26.11                                                            
                                                                                                             
  **8**          Brown            122.3     (30.49)                           (2.56)     (19.15)   (20.78)   71
  30.41          2.49             19.12     20.69                                                            

*∗* \[Pt~3~(**L**^**1**^)~2~(Cl)~9~(H~2~O)~3~\].3Cl.3H~2~O (**1**), \[Pt~3~(**L**^**2**^)~2~(Cl)~9~(H~2~O)~3~\].3Cl (**2**), \[Pt~3~(**L**^**3**^)~2~(Cl)~9~(H~2~O)~3~\].3Cl (**3**), \[Pt~2~(**L**^**4**^)~2~(Cl)~6~(H~2~O)~2~\] .2Cl.4H~2~O (**4**), \[Pd~3~(**L**^**1**^)~2~(H~2~O)~6~\].3Cl~2~ (**5**), \[Pd~3~(**L**^**2**^)~2~(H~2~O)~6~\].3Cl~2~ (**6**), \[Pd~3~(**L**^**3**^)~2~(H~2~O)~6~\] .3Cl~2~ (**7**) and \[Pd~2~(**L**^**4**^)~2~(H~2~O)~4~\].2Cl~2~ (**8**).

###### 

FT-IR spectral band assignments of **L**^**1**^, **L**^**2**^, **L**^**3**^, and **L**^**4**^ ligands and their complexes.

  Compounds       FTIR spectral assignments (cm^−1^)                        
  --------------- ------------------------------------ ------ ------ ------ ----------
  **L** ^**1**^   3249-3112                            1623   1559   1488   \-
                                                                            
  **L** ^**2**^   3260-3142                            1619   1555   1485   \-
                                                                            
  **L** ^**3**^   3251-3156                            1621   1586   1510   \-
                                                                            
  **L** ^**4**^   3244-3150                            1619   1574   1484   \-
                                                                            
  **1**           3200                                 1679   1560   1385   545, 447
                                                                            
  **2**           \-                                   1667   1537   1383   536, 441
                                                                            
  **3**           \-                                   1698   1585   1382   570, 470
                                                                            
  **4**           \-                                   1695   1567   1390   530, 469
                                                                            
  **5**           \-                                   1689   1530   1394   537, 440
                                                                            
  **6**           \-                                   1695   1557   1396   540, 463
                                                                            
  **7**           \-                                   1698   1550   1391   537, 467
                                                                            
  **8**           \-                                   1691   1537   1393   537, 463

###### 

Thermo gravimetric data of Pt(IV) and Pd(II) triazine complexes.

  Complexes       DTG~max~                          Total weight loss   Total residual                     
  --------------- --------------------------------- ------------------- ----------------------------- ---- ----------------------
  **1**           100                               74                  3H~2~O uncoord                26   PtO~2~ + Few carbons
  300, 380, 600   2**L**^**1**^+6Cl~2~                                                                     
                                                                                                           
  **2**           100                               70                  3H~2~O coord                  30   PtO~2~ + Few carbons
  310, 380, 580   2**L**^**2**^+6Cl~2~                                                                     
                                                                                                           
  **3**           100                               68                  3H~2~O coord                  32   PtO~2~ + Few carbons
  370, 580, 700   2**L**^**3**^+6Cl~2~                                                                     
                                                                                                           
  **4**           100                               72                  4H~2~O uncoord                28   PtO~2~ + Few carbons
  280, 380, 700   2**L**^**4**^+4Cl~2~**+**2H~2~O                                                          
                                                                                                           
  **5**           230, 360, 620                     75                  2**L**^**1**^+3Cl~2~+6H~2~O   25   PdO + Few carbons
                                                                                                           
  **6**           360, 420, 800                     75                  2**L**^**2**^+3Cl~2~+6H~2~O   25   PdO + Few carbons
                                                                                                           
  **7**           300, 360, 650                     78                  2**L**^**3**^+3Cl~2~+6H~2~O   22   PdO + Few carbons
                                                                                                           
  **8**           380, 620, 800                     82                  2**L**^**4**^+2Cl~2~+4H~2~O   18   PdO + Few carbons

###### 

Inhibition zone diameter of free ligands and its Pt(IV) and Pd(II) complexes.

  Sample                             Inhibition zone diameter (mm/mg Sample)                     
  ---------------------------------- ----------------------------------------- ----- ----- ----- -----
  Standard                           Ampicillin: Antibacterial agent           30    24    \--   \--
  Amphotericin B: Antifungal agent   \--                                       \--   16    21    
                                                                                                 
  Control: DMSO                      0.0                                       0.0   0.0   0.0   
                                                                                                 
  **L** ^**1**^                      11                                        10    10    0.0   
                                                                                                 
  **L** ^**2**^                      0.0                                       0.0   0.0   0.0   
                                                                                                 
  **L** ^**3**^                      0.0                                       0.0   0.0   0.0   
                                                                                                 
  **L** ^**4**^                      15                                        10    0.0   0.0   
                                                                                                 
  **1**                              19                                        18    16    0.0   
                                                                                                 
  **2**                              12                                        11    0.0   0.0   
                                                                                                 
  **3**                              24                                        23    12    0.0   
                                                                                                 
  **4**                              14                                        12    0.0   0.0   
                                                                                                 
  **5**                              14                                        15    15    0.0   
                                                                                                 
  **6**                              11                                        11    0.0   0.0   
                                                                                                 
  **7**                              16                                        17    12    0.0   
                                                                                                 
  **8**                              14                                        15    11    0.0   

*∗*Ampicillin and amphotericin B are standards of antibacterial and antifungal agents.

###### 

IC~50~ activity of the free ligands and its Pt(IV) complexes.

  ------------------------------------------- --------------- --------------- -------- --------------- ------- --------------- ------- ------
  Against human colon cancer cell lines                                                                                                
                                                                                                                                       
  Concentration (*μ*g/mL)                     Viability (%)                                                                            
  **L** ^**1**^                               **1**           **L** ^**2**^   **2**    **L** ^**3**^   **3**   **L** ^**4**^   **4**   
                                                                                                                                       
  100                                         65              66              61       72.7            55.3    6.4             35.5    44.6
                                                                                                                                       
  50                                          70              67.8            64.4     81.7            60      31.8            41.4    56.6
                                                                                                                                       
  10                                          72              70              69.3     82.5            65      62.9            66.8    71.5
                                                                                                                                       
  IC~50~                                      170             461             277      259             162.8   27              50.7    79
                                                                                                                                       
  Against human lung cancer A549 cell lines                                                                                            
                                                                                                                                       
  Concentration (*μ*g/mL)                     Viability (%)                                                                            
  **L** ^**1**^                               **1**           **L** ^**2**^   **2**    **L** ^**3**^   **3**   **L** ^**4**^   **4**   
                                                                                                                                       
  150                                         82.4            100             96       100             100     44.6            100     77.7
                                                                                                                                       
  100                                         83.4            100             98.7     100             100     61.7            100     100
                                                                                                                                       
  50                                          86              100             100      100             100     66.5            100     100
                                                                                                                                       
  10                                          98.7            100             100      100             100     100             100     100
                                                                                                                                       
  IC~50~                                      431.4           \-              1305.7   \-              \-      128             \-      212
  ------------------------------------------- --------------- --------------- -------- --------------- ------- --------------- ------- ------

[^1]: Academic Editor: Jinsong Ren
